In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident.
Hence, biomarkers need to be developed that enable the stratification of patients with CRC …

Over the past decade there have been significant advances in the molecular
characterization of colorectal cancer (CRC) that are driving treatment decisions. Expanded …

While surgery is the cornerstone treatment for early-stage colorectal cancer, chemotherapy
is the first treatment option for metastatic disease when tumor lesions are frequently not fully …

Metastatic colorectal cancer (mCRC) carries a poor prognosis with an overall 5-year survival
of 13.1%. Therapies guided by tumor profiling have suggested benefit in advanced cancer …

Treatment algorithms and survival for patients with metastatic colorectal cancer have
changed dramatically over the past decade, largely due to the advent of molecularly …

Colorectal cancer (CRC) remains a serious health problem worldwide. Approximately half of
patients will develop distant metastasis after CRC resection, usually with very poor …

Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and
genetic characteristics, allowing the development of therapeutic strategies, based on …

Metastatic colorectal cancer (mCRC) remains incurable in most cases, but survival has
improved with advances in cytotoxic chemotherapy and targeted agents. However, the …

More therapeutic options are now available than ever before for patients with metastatic
colorectal cancer (mCRC) and, as such, treatment decisions have become more complex. A …

Opinion statement The advances made in the therapeutic management of colorectal cancer
(CRC) over recent years with the addition of therapies targeting angiogenesis or cell …